Recombinant Mouse PCSK9 Protein, His-tagged(C-ter)
|Product Overview :||Recombinant Mouse PCSK9 Protein with His tag (C-ter) was expressed in HEK293.|
- Gene Information
- Related Products
|Description :||This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]|
|Protein Length :||Gln35-Gln694|
|Endotoxin :||Endotoxin level is less than 0.1 EU/μg of the protein, as determined by the LAL test.|
|Purity :||> 97% (by SDS-PAGE)|
|Applications :||Binding, SDS-PAGE|
|Notes :||For laboratory research only, not for drug, diagnostic or other use.|
|Storage :||Lyophilized protein should be stored at -20°C or -80°C. After reconstitution, aliquot and store at -20°C for up to one month, at 2-8°C for up to one week. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening.|
|Storage Buffer :||PBS (pH 7.4)|
|Reconstitution :||Reconstitute to a concentration of 0.1-0.5 mg/ml in sterile distilled water.|
|Gene Name :||Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Mus musculus ]|
|Official Symbol :||Pcsk9|
|Synonyms :||PCSK9; proprotein convertase subtilisin/kexin type 9; NARC-1; convertase subtilisin; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409;|
|Gene ID :||100102|
|mRNA Refseq :||NM_153565|
|Protein Refseq :||NP_705793|
|◆ Recombinant Protein|
|PCSK9-33H||Recombinant Human PCSK9 Protein, C-AVI tagged, Biotinylated||+Inquiry|
|PCSK9-040H||Active Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-410H||Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-405C||Recombinant Cynomolgus monkey PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-407H||Recombinant Human PCSK9 Protein, His-tagged||+Inquiry|
|PCSK9-2564MCL||Recombinant Mouse PCSK9 cell lysate||+Inquiry|
|PCSK9-2306RCL||Recombinant Rat PCSK9 cell lysate||+Inquiry|
|PCSK9-2775RCL||Recombinant Rhesus PCSK9 cell lysate||+Inquiry|
|◆ Assay kits|
|Kit-1806||PCSK9(D374T)-LDLR TR-FRET Assay Kit||+Inquiry|
|Kit-1807||PCSK9[Biotinylated]-LDLR Binding Assay Kit||+Inquiry|
|Kit-1808||PCSK9-LDLR TR-FRET Assay Kit||+Inquiry|
|Kit-0665||PCSK9-BIRC2 in vitro Binding Assay Kit||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Customer Reviews (0)Write a review
Ask a Question for All PCSK9 Products
Required fields are marked with *
My Review for All PCSK9 Products
Required fields are marked with *